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SIGNIFICANCE
Psoriasis treatment goals defined in terms of the absolute 
Psoriasis Area and Severity Index (PASI) scores offer cer-
tain advantages in the clinical setting, but a consensus on 
a treatment goal based on absolute PASI has not yet been 
achieved. The current study was conducted in order to eva-
luate different absolute PASI treatment targets relative to 
other measures of the response to treatment based on the 
data derived from two large clinical studies of patients with 
moderate-to-severe plaque psoriasis. These data indicate 
that PASI ≤ 2 represents significantly meaningful clinical 
and health-related quality of life improvements and may be 
a suitable treatment target for moderate-to-severe plaque 
psoriasis.
Treatment goals defined by the absolute Psoria-
sis Area and Severity Index (PASI) scores offer cer-
tain advantages in the clinical setting. In order to 
investigate potential treatment targets, this study 
evaluated absolute PASI outcomes relative to other 
measures of response using data from two randomi-
zed clinical trials of patients with moderate-to-severe 
psoriasis treated with ixekizumab, etanercept, or pla-
cebo (n=2,567). Response was assessed throughout 
12 weeks as the proportion of patients achieving ab-
solute PASI band cut-offs who also reached establis-
hed response criteria. Most PASI band ≤2 responders 
also achieved PASI 90 (70.1–100%), static Physician’s 
Global Assessment (0,1) (91.3–96.1%), Dermatology 
Life Quality Index (0,1) (63.0–67.7%), Patient Global 
Assessment of Disease Severity (0,1) (80.3–86.7%), 
and Itch Numeric Rating Scale improvement ≥4 
(87.2–87.6%). Agreement sharply decreased for less 
stringent PASI criteria. These data indicate that PASI 
≤2 represents significantly meaningful clinical and 
health-related quality of life improvements and may 
be a suitable treatment target for moderate-to-severe 
plaque psoriasis.
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Psoriasis is a chronic inflammatory disease of the skin, nails, and joints that affects at least 100 mil-
lion people worldwide (1). Typical cutaneous signs of 
the disease are erythematous raised lesions covered by 
white or silvery scales. Itching, stinging, and pain are 
common symptoms. Psoriasis can be associated with 
several comorbidities, such as metabolic syndrome and 
cardiovascular disease, which add to its physical and 
psychological burden, negatively affecting the patient’s 
health-related quality of life (HRQoL) (1–3).
Optimal management of psoriasis requires well-defined 
treatment goals based on reproducible and objective as-
sessment methods of the disease severity. The Psoriasis 
Area and Severity Index (PASI) is a widely used tool for 
evaluating the severity and extent of psoriasis, which takes 
into consideration the intensity of erythema, desquama-
tion, and induration present as well as the percentage 
of body surface area involved for the head, trunk, and 
extremities (3, 4). An overall composite score from 0 to 
72 is calculated, with higher scores indicating greater 
disease severity (3, 4). In clinical studies, a reduction from 
baseline in absolute PASI score of ≥75% (PASI 75) or 
≥ 90% (PASI 90) is recommended as a primary endpoint to 
assess the treatment efficacy by the European Medicines 
Agency (5). Moreover, PASI 75 and PASI 90 responses 
have been found to be positively associated with patients’ 
HRQoL assessments, indicative of clinically meaningful 
improvements in the disease activity (2, 6). However, 
the use of relative PASI measures has some limitations. 
Notably, calculation of the relative PASI requires know-
ledge of the baseline disease status, which may not be 
known in routine clinical practice or other clinical settings 
where patients may switch from other treatments without 
a washout period (7). Further, patients, particularly those 
with moderate-to-severe disease, may reach PASI 75 or 
PASI 90 relative to their initial disease status but still 
have significant disease activity and HRQoL problems 
(2, 6). As the absolute PASI has the advantage of being 
indicative of the individual patient’s severity of disease at 
the time of analysis, independent of baseline PASI score, 
use of alternative treatment targets based on the absolute 
PASI scores have been proposed for assessment the ef-
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fectiveness of new treatments (6). Previously, PASI ≤ 2, 
≤ 3, and ≤ 5 have been suggested as potential therapeutic 
targets; however, the level of absolute PASI that could 
serve as an optimal treatment target for clinical studies 
and real-world use is currently unclear (2, 6−8). 
To investigate this, we performed a post hoc analysis 
of the pooled efficacy data from patients in two phase 3 
trials on ixekizumab, a high-affinity humanized mono-
clonal antibody that selectively targets interleukin-17A, 
for the treatment of moderate-to-severe plaque psoriasis 
in adults. In the UNCOVER-2 and UNCOVER-3 trials, 
ixekizumab demonstrated a favorable safety profile and 
clear clinical benefits, with superior efficacy to both 
placebo and the tumor necrosis factor-alpha inhibitor 
etanercept in terms of PASI 75, PASI 90, and PASI 100 
responses following a 12-week induction phase (9). The 
current analysis is based on the data collected throughout 
12 weeks of treatment (induction period) and aims to 
determine the degree of overlap in responders meeting 
various absolute PASI and relative PASI criteria to 
identify a level of absolute PASI that could serve as an 
alternative treatment goal. To further validate potential 
treatment targets, absolute PASI responders were also 
evaluated against responders defined by another com-
monly used clinical index of disease severity, the static 
Physician’s Global Assessment (sPGA), and multiple 
patient-reported outcomes in order to determine the abso-
lute PASI targets representing meaningful improvement 
in disease activity and HRQoL.
METHODS
Patients
This is a post hoc analysis of the pooled efficacy data from 
patients in two randomized, double-blind, placebo- and active-
controlled phase 3 clinical trials, UNCOVER-2 and UNCOVER-3 
(NCT01597245 and NCT01646177, respectively), comparing 
etanercept and ixekizumab efficacy and safety profiles in adult 
patients with moderate-to-severe plaque psoriasis. The eligibility 
criteria for the studies were similar and have been previously pu-
blished (9). Briefly, the studies included patients ≥ 18 years of age 
with a confirmed diagnosis of chronic moderate-to-severe plaque 
psoriasis ≥ 6 months prior to the baseline with a minimum 10% 
body surface area involvement, an sPGA score ≥ 3 (0–5 scale, in 
order of increasing severity), and a PASI score ≥ 12 at screening 
and baseline visits. Key exclusion criteria included any active or 
recent infections at baseline; erythrodermic, generalized pustular, 
or guttate forms of psoriasis; and prior exposure to etanercept (9). 
All studies were conducted with the approval of each center’s 
institutional review board or independent ethics committee and 
in accordance with the guiding principles of the Declaration of 
Helsinki. All patients provided written informed consent prior to 
enrollment.
Study design, treatments, and endpoints
The original designs for the two studies have been published 
previously (9). The current analysis is based on the data collected 
during the 12-week induction periods of these studies, where the 
response to the two treatment regimens of ixekizumab, the active 
comparator etanercept, and placebo has been compared. Patients 
were randomly assigned 2:2:2:1 to receive subcutaneous 160 mg ix-
ekizumab (starting dose) followed by 80 mg every 2 weeks (Q2W) 
or 4 weeks (Q4W), etanercept 50 mg twice weekly, or placebo. 
Efficacy measures of interest in the current analysis included 
assessments of disease activity, including the proportion of patients 
achieving PASI 75, PASI 90, and absolute PASI criteria of ≤ 1, 
≤ 2, ≤ 3, and ≤ 5 following 1, 2, 4, 8, and 12 weeks of treatment. 
To gain further insight into the distribution of responses at each 
time point, absolute PASI response data from the original studies 
were regrouped into 6 non-overlapping categories representing 
the proportion of patients reaching absolute PASI bands: PASI = 0; 
PASI > 0 to ≤ 1; PASI > 1 to ≤ 2; PASI > 2 to ≤ 3; PASI > 3 to ≤ 5; 
and PASI > 5. The proportion of patients per treatment group 
achieving each absolute PASI band criterion was assessed at each 
study endpoint in the induction phase.
Using data pooled across all treatments, the percentage overlap 
between each population of absolute PASI band response and 
the populations of PASI 75, PASI 90, and sPGA responders at 
week 12 was also determined. Treatment response for the sPGA 
was considered as achieving scores of 0 (clear) or 1 (minimal di-
sease). Patient-reported outcomes reflective of HRQoL were also 
examined in this manner and included the proportion of patients 
showing improvement on the Dermatology Life Quality Index 
(DLQI), the Itch Numeric Rating Scale (NRS), and the Patient 
Global Assessment of Disease Severity (PatGA). The DLQI is a 
self-administered instrument that consists of 10 questions rating 
the impact of skin symptoms on various HRQoL domains over the 
previous 7 days, for a possible composite score of up to 30 (10). 
The current analyses used DLQI (0,1) as the response criterion, 
indicative of no effect of psoriasis or psoriasis treatment on the 
patient’s life (11). The Itch NRS is an instrument comprising of one 
question, with scores from no itch to worst itch imaginable (from 0 
to 10) in the past 24 h (12). Treatment response was defined herein 
as a ≥4-point improvement from baseline on the Itch NRS. The 
PatGA is a single-item questionnaire in which the patient scores 
their symptoms on a 0–5 NRS (clear to severe), with a score of 0 
or 1 set as the response criterion for this study.
Assessments of the 12-week response by baseline PASI
To determine whether the baseline PASI affected the response to 
treatment, the proportion of patients reaching each absolute PASI 
band criterion at week 12 were assessed after categorizing patients 
into groups with baseline PASI < 20 or baseline PASI ≥ 20. Mean 
DLQI, PatGA, and Itch NRS at week 12 were also summarized 
overall and by baseline PASI category.
Statistical analyses
This was a post hoc analysis of pooled data collected from the 
intent-to-treat populations from two phase 3 clinical trials. The 
data cut-off date for this analysis was September 1, 2015. For cate-
gorical variables, missing data were imputed using non-responder 
imputation (NRI) for binary endpoints or last-observation carried 
forward (LOCF) for continuous outcomes. NRI assumes that every 
patient who discontinues is a non-responder; LOCF assumes that 
discontinued patients will have the same efficacy response for the 
remainder of the study. As the Q4W (every 4 weeks) ixekizumab 
regimen is not approved for use in the European Union, the Q4W 
data are only included in the integrated analyses of all treatments 
combined, and data for Q2W (every 2 weeks) (the approved 
dose) alone are otherwise shown in comparisons to placebo and 
etanercept treatment.
For comparisons between the proportions of patients meeting 
absolute PASI criteria by treatment group, a Cochran-Mantel- 
Haenszel test stratified by study was performed. Two-sided statisti-
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cal tests were performed where p < 0.05 was considered statistically 
significant. Due to the exploratory nature of these analyses, no 
correction for multiplicity was performed. To compare the absolute 
PASI measures to other well-established indices of disease severity 
and HRQoL, the percentage of patients reaching each criterion of 
interest (PASI 75, PASI 90, sPGA [0,1], DLQI [0,1], PatGA [0,1], 
and Itch NRS improvement ≥ 4) who also reached each absolute 
PASI band cutoff was determined. For these analyses, all patients 
with data available at baseline and week 12 were pooled across 
treatment groups.
RESULTS
Patient disposition
A total of 2,570 patients participated in the two studies. 
Patient disposition and clinical details for the individual 
studies have been previously reported in detail (9). An 
overview of patient disposition of the combined studies 
throughout the 12-week induction phase is provided in 
Fig. 1. For the current analyses, 3 subjects were excluded 
from the absolute PASI band analyses due to the missing 
baseline values on several measures.
Table I shows selected summary demographics and 
baseline characteristics by treatment group for the com-
bined studies. Across treatment groups, the patients had 
similar baseline characteristics, the majority comprising 
of white males with the mean psoriasis duration > 18 
years and mean body surface area involvement of  > 26% 
(Table I). Approximately 60% of patients had previously 
received at least one form of systemic therapy for psoria-
sis (Table I). The mean ± standard deviation (SD) baseline 
PASI score across all treatment groups was 20.29 ± 7.76 
(range 12.0–63.0; median = 17.90). 
Efficacy assessments based on absolute PASI and PASI 
band response rates
As previously reported in terms of the relative PASI 
response rates (9), the absolute PASI response rates for 
ixekizumab Q2W treatment were significantly higher 
across the 12-week induction period compared to the 
response rates for the placebo and etanercept treatment 
groups (Fig. 2). Notably, by week 2, a significantly grea-
ter proportion of patients in the ixekizumab treatment 
group reached PASI ≤ 1, and differences were sustained 
at all endpoints through 12 weeks (week 12 PASI ≤ 1 
response rates: 54.6% ixekizumab vs. 13.4% etanercept 
vs. 0.8% placebo, p < 0.001; Fig. 2). Similar results were 
obtained for PASI ≤ 2, ≤ 3, and ≤ 5, with significant diffe-
rences in response to ixekizumab compared to etanercept 
or placebo detected as early as week 1 for the absolute 
PASI ≤ 3 and ≤ 5 criteria (Fig. 2).
Table I. Baseline demographics and clinical characteristics of patients with moderate-to-severe psoriasis: integrated analysis of UNCOVER-2 
and UNCOVER-3
Characteristics
Placebo
n = 361
IXE Q2W
n = 736
Etanercept
n = 740
Age, years, mean ± SD 45.9 ± 12.12 45.1 ± 13.18 45.5 ± 13.33
Sex, male, n (%) 257 (71.2) 475 (64.5) 505 (68.2)
Race, white, n (%) 325 (90.0) 691 (94.0) 682 (92.7)
Body mass index (kg/m2), mean ± SD 30.52 ± 6.72 30.15 ± 7.08 30.98 ± 7.43
Psoriasis duration, years, mean ± SD 18.62 ± 12.60 18.06 ± 12.15 18.50 ± 12.11
Body surface area involvement, %, mean ± SD 28.0 ± 17.75 26.6 ± 16.66 26.8 ± 16.58
Static Physician’s Global Assessment, mean ± SD 3.6 ± 0.61 3.5 ± 0.61 3.5 ± 0.58
Dermatology Life Quality Index, mean ± SD 12.8 ± 7.10 12.4 ± 6.89 12.0 ± 6.95
Psoriasis Area and Severity Index score, mean ± SD 20.86 ± 8.37 20.07 ± 7.81 19.90 ± 7.53
Itch numeric rating scale, mean ± SD 6.4 ± 2.65 6.5 ± 2.56 6.4 ± 2.61
Previous systemic history, n (%)
  None 152 (42.1) 296 (40.2) 293 (39.6)
  Nonbiologic 133 (36.8) 298 (40.5) 311 (42.0)
  Biologic 35 (9.7) 54 (7.3) 59 (8.0)
  Nonbiologic and biologic 41 (11.4) 88 (12.0) 77 (10.4)
IXE Q2W: ixekizumab 80 mg every 2 weeks; SD: standard deviation.
Fig. 1. Patient disposition during the 
12-week induction period of UNCOVER-2 
and UNCOVER-3. Three additional patients 
who were randomized were excluded from the 
Psoriasis Area Severity Index (PASI) band 
analyses due to the missing baseline data. 
Ixekizumab 80 mg every 4 weeks (IXEQ4W) 
data are only included in the all-treatment-
combined analyses. ETN: etanercept; 
IXEQ2W: ixekizumab 80 mg every 2 weeks; 
PBO: placebo. (Data from Ref. 9).
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Fig. 3 illustrates the differences in the distribution of 
responses to each treatment in terms of non-overlapping 
absolute PASI band categories. This breakdown of  data 
indicates that, compared to patients who received etaner-
cept or placebo, more patients treated with ixekizumab 
were distributed across the lower absolute PASI catego-
ries at all time points during the 12 weeks of treatment 
(Fig. 3). For example, at week 12, 80.8% of patients in 
the ixekizumab treatment group were categorized as ≤ 3 
responders compared to 34.8% in the etanercept group 
and 3.7% in the placebo group, respectively.
Disease severity and HRQoL by absolute PASI response 
category
The proportion of responders across all treatments at 
week 12 for each absolute PASI band criterion was 
further examined relative to response on other disease 
severity indices (Table II). At week 12, of the patients 
classified as absolute PASI band > 0 to ≤ 1 responders, 
100% of patients also met PASI 90 and 96.1% met sPGA 
(0,1), indicating excellent agreement between these re-
sponse criteria. Similarly, the majority of patients with 
an absolute PASI > 1 to ≤ 2 response at week 12 also had 
a PASI 90 (70.1%) and sPGA (0,1) (91.3%) response, 
but the level of agreement sharply decreased thereafter 
for decreasingly stringent absolute PASI band criteria 
(Table II).
Regarding the patient-reported outcomes, across all 
treatments combined, a high proportion of patients 
(81.8%) classified as absolute PASI=0 (PASI 100) re-
sponders at 12 weeks reached DLQI (0,1), indicative of 
no impact of disease on patients’ lives (Table II). The 
percentage overlap with DLQI (0,1) responders fell to 
67.7% and 63.0%, respectively, for absolute PASI >0 to 
≤ 1 and > 1 to ≤ 2 responders, and continued to gradually 
decrease with decreasing absolute PASI band ranges 
(Table II). In comparison, DLQI (0,1) was met by 67.2% 
of PASI 75 and 73.4% of PASI 90 responders (Table II). 
For the other HRQoL measures examined, the proportion 
of patients classified as absolute PASI = 0 responders at 
12 weeks who also reached PatGA (0,1) and Itch NRS 
(≥ 4 improvement) was 96.0% and 94.7%, respectively 
(Table II). Of the patients with absolute PASI > 0 to ≤ 1 
or > 1 to ≤  2 responses, 86.7% and 80.3%, respectively, 
were also classified as PatGA (0,1) responders, and > 87% 
of patients in these absolute PASI categories also had a 
≥ 4-point improvement on the Itch NRS (Table II). How-
% Patients 
 Week 1 Week 2 Week 4 Week 8 Week 12 
Absolute PASI 
criteria 
IXE 
Q2W ETN PBO 
IXE 
Q2W ETN PBO 
IXE 
Q2W ETN PBO 
IXE 
Q2W ETN PBO 
IXE 
Q2W ETN PBO 
PASI = 0 0.0 0.0 0.0 1.5 0.0 0.0 8.2 0.4 0.0 24.7 2.8 0.8 39.0 6.4 0.3 
PASI >0 to <=1 0.1 0.0 0.0 1.1 0.0 0.0 5.2 0.7 0.3 13.7 3.1 0.0 15.6 7.0 0.6 
PASI >1 to <=2 0.3 0.0 0.0 3.7 0.1 0.0 13.3 1.2 0.3 20.0 6.6 0.3 17.0 11.9 1.4 
PASI >2 to <=3 0.8 0.3 0.0 5.2 0.9 0.3 10.7 3.4 0.8 10.1 8.8 0.8 9.2 9.5 1.4 
PASI >3 to <=5 4.5 0.4 0.0 14.0 2.0 0.3 17.1 8.9 1.1 12.4 13.5 2.2 8.4 15.9 2.5 
PASI >5 94.3 99.3 100.0 74.5 97.0 99.4 45.5 85.4 97.5 19.1 65.2 95.9 10.8 49.3 93.8 
Fig. 3. Comparison of relative response rates across 
treatment groups (non-responder imputation 
(NRI)) using absolute Psoriasis Area Severity Index 
(PASI) band criteria at 1, 2, 4, 8, and 12 weeks. The 
relative proportions of patients reaching each absolute 
PASI criterion are shown by treatment group and time 
point. ETN: etanercept; IXE Q2W: ixekizumab 80 mg 
every 2 weeks; PBO: placebo.
Fig. 2. Proportion of patients achieving absolute Psoriasis Area Severity Index (PASI) criteria from baseline through week 12 (non-
responder imputation (NRI)) of UNCOVER-2 and UNCOVER-3. Percentages for each time point are color coded by treatment group. p-value from 
Cochran-Mantel-Haenszel test stratified by study. a) Placebo (PBO) at p < 0.001; b) vs Etanercept (ETN) at p < 0.001; c) vs PBO at p < 0.05; d) vs ETN 
at p < 0.05. For simplicity, zero values are not labeled.; IXE Q2W: ixekizumab 80 mg every 2 weeks.
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ever, the degree of overlap between > 2 to ≤ 3 or > 3 to 
≤  5 response and these response criteria was substantially 
lower at 56.3–67.2% for PatGA (0,1) and 75.0–79.2% 
for Itch NRS (≥ 4) (Table II).
Mean absolute DLQI, PatGA, and Itch NRS scores 
are summarized by absolute PASI band criteria in Table 
III, and the overall means are plotted relative to absolute 
band criteria in Fig. 4. Absolute DLQI, PatGA, and Itch 
NRS scores at week 12 correlated with the absolute PASI 
criteria, with the impact of skin symptoms on HRQoL 
rated as less severe by patients in the absolute PASI ≤  2 
categories compared to patients in the absolute PASI > 2 
categories (Fig. 4). 
Assessment of the 12-week response by baseline PASI 
< 20 versus baseline PASI ≥ 20 revealed no differences in 
the percentage of patients reaching each absolute PASI 
criterion between the two groups (Fig. 5). Furthermore, 
when the mean absolute DLQI, PatGA, and Itch NRS 
scores were assessed by these baseline PASI categories, 
no consistent differences were observed (Table III).
DISCUSSION
Relative PASI response criteria are commonly used in 
clinical trials and for comparing newer and older treat-
ments but have limitations when applied in the daily 
clinical practice. Treatment goals defined in terms of 
absolute PASI avoid some of these limitations, but a 
consensus on the absolute PASI target that is clinically 
meaningful has not been reached. The current study was 
conducted to inform this discussion and to evaluate dif-
ferent absolute PASI treatment targets relative to other 
measures of response based on data derived from two 
large clinical studies on patients with moderate-to-severe 
plaque psoriasis.
The ultimate treatment goal for psoriasis is clear or 
almost clear skin, with many clinicians now advocating 
robust treatment goals of ≥ 90% improvement over 
Table II. Patients who reached relative Psoriasis Area and Severity Index (PASI), static Physician’s Global Assessment (sPGA), and patient-
reported outcome criteria at week 12 (NRI) as a percentage of those patients achieving each absolute PASI band (all treatments combined)
PASI 75
n = 2,567
PASI 90
n = 2,567
sPGA (0,1)
n = 2,567
DLQI (0,1)
n = 2,567
PatGA (0,1)
n = 2,567
Itch NRS ≥4b
n = 2,140
Absolute PASI = 0
  n (%) reaching criterion
Nx = 577
577 (100)
Nx = 577
577 (100)
Nx = 577
576 (99.8)
Nx = 577
472 (81.8)
Nx = 577
554 (96.0)
Nx = 473
448 (94.7)
Absolute PASI > 0 to ≤ 1
  n (%) reaching criterion
Nx = 279
279 (100)
Nx = 279
279 (100)
Nx = 279
268 (96.1)
Nx = 279
189 (67.7)
Nx = 279
242 (86.7)
Nx = 235
205 (87.2)
Absolute PASI > 1 to ≤ 2
  n (%) reaching criterion
Nx = 335
335 (100)
Nx = 335
235 (70.1)
Nx = 335
306 (91.3)
Nx = 335
211 (63.0)
Nx = 335
269 (80.3)
Nx = 275
241 (87.6)
Absolute PASI > 2 to ≤ 3
  n (%) reaching criterion
Nx = 201
201 (100)
Nx = 201
41 (20.4)
Nx = 201
143 (71.1)
Nx = 201
112 (55.7)
Nx = 201
135 (67.2)
Nx = 168
133 (79.2)
Absolute PASI > 3 to ≤ 5
  n (%) reaching criterion
Nx = 256
173 (67.6)
Nx = 256
9 (3.5)
Nx = 256
110 (43.0)
Nx = 256
118 (46.1)
Nx = 256
144 (56.3)
Nx = 216
162 (75.0)
Absolute PASI >5a
  n (%) reaching criterion
Nx = 919
51 (5.5)
Nx = 919
0 (0)
Nx = 919
48 (5.2)
Nx = 919
139 (15.1)
Nx = 919
138 (15.0)
Nx = 773
237 (30.7)
PASI 75
  n (%) reaching criterion
Nx = 1,616
1,616 (100)
Nx = 1,616
1,141 (70.6)
Nx = 1,616
1,403 (86.8)
Nx = 1,616
1086 (67.2)
Nx = 1,616
1332 (82.4)
Nx = 1,616
1,173 (72.6)
PASI 90
  n (%) reaching criterion
Nx = 1,141
1,141 (100)
Nx = 1,141
1,141 (100)
Nx = 1,141
1,095 (96.0)
Nx = 1,141
838 (73.4)
Nx = 1,141
1,017 (89.1)
Nx = 1,141
866 (75.9)
aCategory includes patients with missing data. bItch numeric rating scale (NRS) ≥ 4 refers to improvement from baseline.
%n= n/Nx*100; DLQI: Dermatology Life Quality Index; N: total number of patients in the analysis population; n: number of patients meeting the specified criteria; Nx: 
number of patients in each PASI category; PatGA: Patient Global Assessment.
Table III. Mean and mean change from baseline in DLQI, PatGA, 
and Itch NRS at Week 12 (LOCF) by PASI band response (all 
treatments combined)
DLQIa
n= 2,570
Mean (SD)
PatGAb
n= 2,570
Mean (SD)
Itch NRSc
n= 2,131
Mean (SD)
Absolute PASI = 0
Overall mean
  Mean change from baseline
Mean by baseline PASI category
  Baseline PASI <20
  Baseline PASI ≥20
  0.73 (1.48)
–9.80 (6.92)
  0.97 (1.82)
  0.40 (0.68)
  0.39 (0.53)
–3.45 (1.06)
  0.45 (0.57)
  0.30 (0.47)
  0.53 (0.93)
–6.53 (1.96)
  0.75 (1.16)
  0.30 (0.57)
Absolute PASI > 0 to ≤ 1
Overall mean
  Mean change from baseline
Mean by baseline PASI category
  Baseline PASI <20
  Baseline PASI ≥20
  1.93 (2.52)
–9.50 (7.32)
  2.11 (2.61)
  1.53 (2.35)
  0.98 (0.63)
–2.81 (1.21)
  1.05 (0.62)
  0.82 (0.64)
  1.41 (1.71)
–5.17 (2.43)
  1.45 (1.34)
  1.33 (2.35)
Absolute PASI > 1 to ≤ 2
Overall mean
  Mean change from baseline
Mean by baseline PASI category
  Baseline PASI <20
  Baseline PASI ≥20
  2.00 (2.77)
–9.65 (7.13)
  1.87 (2.32)
  2.27 (3.57)
  1.23 (0.92)
–2.71 (1.32)
  1.13 (0.91)
  1.43 (0.94)
  1.56 (1.51)
–5.24 (2.01)
  1.67 (1.61)
  1.33 (1.31)
Absolute PASI > 2 to ≤ 3
Overall mean
  Mean change from baseline
Mean by baseline PASI category
  Baseline PASI <20
  Baseline PASI ≥20
  3.55 (4.52)
–8.23 (6.41)
  3.84 (4.94)
  2.61 (2.73)
  1.52 (0.78)
–2.40 (1.15)
  1.53 (0.80)
  1.50 (0.71)
  2.26 (2.11)
–4.95 (2.39)
  2.13 (1.94)
  2.63 (2.55)
Absolute PASI > 3 to ≤ 5
Overall mean
  Mean change from baseline
Mean by baseline PASI category
  Baseline PASI <20
  Baseline PASI ≥20
  3.24 (3.50)
–8.67 (5.96)
  3.26 (3.21)
  3.20 (4.40)
  1.61 (0.84)
–2.36 (1.20)
  1.61 (0.80)
  1.60 (1.00)
  2.21 (1.81)
–4.88 (2.36)
  2.17 (1.69)
  2.33 (2.15)
Absolute PASI > 5d
Overall mean
  Mean change from baseline
Mean by baseline PASI category
  Baseline PASI <20
  Baseline PASI ≥20
  8.80 (7.13)
–3.89 (6.46)
  8.24 (6.64)
  9.56 (7.67)
  3.12 (1.29)
–0.97 (1.39)
  3.13 (1.26)
  3.10 (1.34)
  5.46 (2.93)
–2.01 (2.94)
  5.58 (2.84)
  5.31 (3.04)
aDermatology Life Quality Index (DLQI) has a possible composite score of 0–30 
(least to most impact of skin symptoms on health-related quality of life (HRQoL)). 
bPatient Global Assessment (PatGA) has possible scores from 0–5 numeric rating scale 
(NRS) (clear to severe). cItch NRS has scores from no itch to worst itch imaginable 
(from 0 to 10) in the past 24 h. dCategory includes patients with missing data.
ITT: intention to treat; LOCF: last observation carried forward; PASI: Psoriasis 
Area and Severity Index.
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base line PASI, given the increased efficacy of the newer 
treatments (2, 6). With respect to PASI 90, the current 
absolute PASI band analyses showed that both PASI > 0 
to ≤ 1 and > 1 to ≤ 2 responder populations exhibited good 
overlap with the responder populations for PASI 90, as 
well as for sPGA (0,1). In contrast, the levels of overlap 
for PASI > 2 to ≤ 3 and > 3 to ≤ 5 responder populations 
with PASI 90 and sPGA (0,1) were markedly reduced, 
indicating worse agreement between these criteria. These 
data suggest that PASI ≤ 2 might serve as a potential 
alternative treatment goal for patients with plaque pso-
riasis. In support of this conclusion, compared to other 
absolute PASI levels, the PASI ≤ 2 response rates for 
ixekizumab, etanercept, and placebo treatment groups 
at 12 weeks in this pooled analysis most closely match 
the PASI 90 response rates previously published on the 
individual study populations (9).
Further, the current data suggest that absolute PASI 
values in this range (i.e., ≤ 2) reflect clinically meaningful 
improvements in the patients’ HRQoL. Not surprisingly, 
a high proportion of patients achieving absolute PASI = 0 
at 12 weeks also reached DLQI (0,1), PatGA (0,1), 
and Itch NRS ≥ 4, suggesting that skin-related HRQoL 
improvements were strongly associated with achieving 
clear skin, which is consistent with previous reports 
(13−16). Patients showing less than total skin clearance 
at incrementally higher absolute PASI levels had cor-
respondingly less overlap with the responders on these 
HRQoL measures, indicating a substantial reduction in 
patient satisfaction with increasing amounts of residual 
disease. This inverse relationship between PASI level 
and HRQoL benefit was also observed between absolute 
DLQI, PatGA, and Itch NRS scores and absolute PASI 
band response and is in broad agreement with previous 
studies, which used a variety of HRQoL measures (13, 
17, 18). However, the baseline PASI level (baseline PASI 
< 20 versus PASI ≥ 20) did not substantially impact PASI 
response or HRQoL outcomes. These latter findings are 
in line with our previous report on UNCOVER-2 and 
UNCOVER-3 integrated populations, which found no 
differences in PASI response between baseline PASI < 20 
and PASI ≥ 20 groups at 12 weeks and 156 weeks when 
patients were examined by treatment group, indicating 
a consistent response to treatment regardless of the ba-
seline disease severity (19). 
Limitations
This study has a number of limitations. Notably, as this 
study used data from clinical trials on moderate-to-severe 
psoriasis, the study populations were largely homoge-
neous in terms of baseline demographics and clinical cha-
racteristics, including baseline PASI scores. With a mean 
baseline PASI of 20.29, the strong agreement observed 
Fig. 4. Mean Dermatology Life Quality Index (DLQI), Patient Global Assessment (PatGA), and Itch numeric rating scale (NRS) at week 12 
(last observation carried forward (LOCF)) by Psoriasis Area Severity Index (PASI) band response (all treatments combined). DLQI has a 
possible composite score of 0–30 (least to most impact of skin symptoms on health-related quality of life (HRQoL)). PatGA is scored from 0–5 NRS (clear 
to severe). Itch NRS is scored from no itch to worst itch imaginable (from 0 to 10) in the previous 24 h. PASI > 5 category includes patients with missing 
data. Data are from the intention-to-treat population (DLQI, PatGA) or a subpopulation with baseline Itch ≥4 (Itch NRS). N: total number of patients in 
the analysis population; Nx: number of patients in each PASI band category.
Fig. 5. Percentage of patients who reached each absolute 
Psoriasis Area Severity Index (PASI) band criterion at 
week 12 (non-responder imputation (NRI)) by baseline 
PASI (all treatments combined). Response has been 
categorized according to patients with baseline PASI score 
< 20 or ≥ 20.
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
977Absolute PASI as a measure for psoriasis
Acta Derm Venereol 2019
between PASI ≤ 2 and PASI 90 response is to be expec-
ted, and examining the absolute PASI in a more hetero-
geneous patient group with a broader range of base line 
PASI values would further improve the evaluation of the 
absolute PASI treatment targets. An additional limitation 
of using data from the UNCOVER clinical trials is that 
all patients met the inclusion criterion of baseline PASI 
≥ 12, but it is not currently known if the findings are 
relevant to disease activity < 12. A recent prospective 
observational study using the BioCAPTURE registry, 
inclusive of patients from clinical practice with baseline 
PASI scores < 10, has begun to examine this issue; its 
findings suggest that defining treatment goals in terms 
of absolute PASI may also have utility in patients with 
mild disease according to the baseline PASI values (8). 
Conclusion
Using data from clinical studies, the current study sup-
ports the use of absolute PASI to define treatment goals 
as it can be used regardless of knowledge of the baseline 
disease; thereby avoiding some of the limitations of the 
relative PASI measures. Specifically, the data suggest 
that for most patients, PASI ≤ 2 is an attainable goal for 
the treatment of moderate-to-severe plaque psoriasis, on 
par with PASI 90 in terms of its association with clini-
cal and HRQoL improvements, and may be a clinically 
relevant choice if the absolute PASI is used instead of 
the relative PASI. 
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